BioSpace News Archive

Vektor Medical, Inc., a private company founded to develop the next-generation in arrhythmia mapping systems, today announced the publication of results of a dual-site study involving its non-invasive vMap™ system during stereotactic ablative radiotherapy (SAbR), in the peer-reviewed journal, Heart Rhythm O2.

Varian, a Siemens Healthineers company, announced today that China Medical University Hospital in Central Taiwan treated its first patient with Ethos™ therapy, making it the first hospital in Taiwan and within the Greater China region to use Ethos therapy for advanced cancer treatment.

City of Hope today announced the appointment of five new members to the boards of directors of three entities within the City of Hope enterprise

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), today announced that EyeGate’s President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference

atai Life Sciences (Nasdaq: ATAI) (“atai”), today announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD) in collaboration with Kadima Neuropsychiatry.

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of FDS Amplicare.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that it will host a virtual Investor Day on Friday, September 17, 2021, starting at 9:00 a.m. and expected to conclude by 11:00 a.m..

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Rani Therapeutics Holdings, Inc. today announced the appointment of Eric Groen as General Counsel.